Joon Lee
Stock Analyst at Truist Securities
(4.59)
# 241
Out of 4,670 analysts
112
Total ratings
53%
Success rate
33.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joon Lee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Maintains: Buy | $17 → $36 | $14.27 | +152.28% | 3 | Nov 12, 2024 | |
| CPRX Catalyst Pharmaceuticals | Maintains: Buy | $30 → $36 | $21.48 | +67.60% | 7 | Nov 11, 2024 | |
| EDIT Editas Medicine | Maintains: Buy | $12 → $8 | $2.44 | +227.87% | 7 | Nov 5, 2024 | |
| ARGX argenx SE | Maintains: Buy | $540 → $660 | $605.92 | +8.93% | 11 | Oct 31, 2024 | |
| SAGE Sage Therapeutics | Maintains: Hold | $13 → $8 | $5.17 | +54.74% | 11 | Oct 30, 2024 | |
| CRMD CorMedix | Maintains: Buy | $12 → $17 | $9.96 | +70.68% | 7 | Oct 22, 2024 | |
| LBPH Longboard Pharmaceuticals | Downgrades: Hold | $60 | $59.80 | +0.33% | 2 | Oct 15, 2024 | |
| VRNA Verona Pharma | Maintains: Buy | $38 → $44 | $38.81 | +13.37% | 5 | Oct 9, 2024 | |
| CORT Corcept Therapeutics | Maintains: Buy | $65 → $76 | $57.54 | +32.08% | 7 | Sep 30, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $118 → $90 | $64.26 | +40.06% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $40 | $6.04 | +562.25% | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $100 | $47.88 | +108.86% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $508 → $550 | $450.97 | +21.96% | 1 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 | $14.30 | +739.16% | 3 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $0.33 | +2,976.92% | 7 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 | $52.59 | +128.18% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 | $74.50 | +101.34% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 | $98.68 | +52.01% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $65 | $25.86 | +151.35% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $126.67 | +57.89% | 2 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $2.47 | +102.43% | 7 | Sep 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $5.66 | +218.30% | 1 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $280 | $1.43 | +19,480.42% | 1 | Oct 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $27 → $34 | $22.27 | +52.67% | 1 | Mar 16, 2021 |
Wave Life Sciences
Nov 12, 2024
Maintains: Buy
Price Target: $17 → $36
Current: $14.27
Upside: +152.28%
Catalyst Pharmaceuticals
Nov 11, 2024
Maintains: Buy
Price Target: $30 → $36
Current: $21.48
Upside: +67.60%
Editas Medicine
Nov 5, 2024
Maintains: Buy
Price Target: $12 → $8
Current: $2.44
Upside: +227.87%
argenx SE
Oct 31, 2024
Maintains: Buy
Price Target: $540 → $660
Current: $605.92
Upside: +8.93%
Sage Therapeutics
Oct 30, 2024
Maintains: Hold
Price Target: $13 → $8
Current: $5.17
Upside: +54.74%
CorMedix
Oct 22, 2024
Maintains: Buy
Price Target: $12 → $17
Current: $9.96
Upside: +70.68%
Longboard Pharmaceuticals
Oct 15, 2024
Downgrades: Hold
Price Target: $60
Current: $59.80
Upside: +0.33%
Verona Pharma
Oct 9, 2024
Maintains: Buy
Price Target: $38 → $44
Current: $38.81
Upside: +13.37%
Corcept Therapeutics
Sep 30, 2024
Maintains: Buy
Price Target: $65 → $76
Current: $57.54
Upside: +32.08%
BioMarin Pharmaceutical
Sep 17, 2024
Maintains: Buy
Price Target: $118 → $90
Current: $64.26
Upside: +40.06%
Aug 14, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $6.04
Upside: +562.25%
Aug 12, 2024
Maintains: Buy
Price Target: $120 → $100
Current: $47.88
Upside: +108.86%
Aug 5, 2024
Reiterates: Buy
Price Target: $508 → $550
Current: $450.97
Upside: +21.96%
Jun 24, 2024
Maintains: Buy
Price Target: $120
Current: $14.30
Upside: +739.16%
Jun 18, 2024
Maintains: Buy
Price Target: $10
Current: $0.33
Upside: +2,976.92%
Jun 17, 2024
Maintains: Buy
Price Target: $120
Current: $52.59
Upside: +128.18%
May 16, 2024
Maintains: Buy
Price Target: $150
Current: $74.50
Upside: +101.34%
Mar 26, 2024
Maintains: Buy
Price Target: $150
Current: $98.68
Upside: +52.01%
Mar 25, 2024
Reiterates: Buy
Price Target: $65
Current: $25.86
Upside: +151.35%
Mar 20, 2024
Reiterates: Buy
Price Target: $200
Current: $126.67
Upside: +57.89%
Sep 20, 2023
Maintains: Buy
Price Target: $6 → $5
Current: $2.47
Upside: +102.43%
May 10, 2023
Initiates: Buy
Price Target: $18
Current: $5.66
Upside: +218.30%
Oct 20, 2021
Initiates: Buy
Price Target: $280
Current: $1.43
Upside: +19,480.42%
Mar 16, 2021
Upgrades: Buy
Price Target: $27 → $34
Current: $22.27
Upside: +52.67%